NCT06380777 Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia
| NCT ID | NCT06380777 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Sarcopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2023-09-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia. Research aims: Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey. Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions. Participants will: Engage in screening and assessment based on inclusion and exclusion criteria. Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals. Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.
Eligibility Criteria
Inclusion Criteria: * Age ≥45 years; * meeting sarcopenia diagnostic criteria; * consent to participate in this study Exclusion Criteria: * Age \<45 years; * patients in acute phase of chronic illness; * infectious disease patients; * people who lack of independent mobility; * people who lack of communication or cognitive skills; * people who refusal to participate in this study
Contact & Investigator
Kang Yu
STUDY DIRECTOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06380777 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06380777 currently recruiting?
Yes, NCT06380777 is actively recruiting participants. Contact the research team at yuk1997@sina.com for enrollment information.
Where is the NCT06380777 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06380777 clinical trial?
NCT06380777 is sponsored by Peking Union Medical College Hospital. The principal investigator is Kang Yu at Peking Union Medical College Hospital. The trial plans to enroll 10,000 participants.